The study report worldwide Tetanus Toxoid Vaccine Market covers the market analysis for
the regions - North America, Europe, Asia Pacific/ Southeast Asia and Row and country
analysis of China, Japan, and India focusing on top manufacturers in world market and the
market share they hold including their contribution to the market growth
Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle
spasms. The spasms may be very severe and even cause bone fractures. Other symptoms
include fever, sweating, headache, trouble swallowing, hypertension etc. About 10% of
those infected, die while a large number become incapacitated due to bone fractures.
Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing
immunity against the pathogen causing tetanus. The general dosage recommendation is five
doses during childhood, with a sixth given during adolescence with additional doses every
10 years. The tetanus vaccine was initially developed in 1924 and has resulted in a 95%
decrease in the rate of tetanus in the US and is on the World Health Organization's List of
Essential Medicines. The vaccine also is considered very safe even during pregnancy and for
those with HIV.
The market restraints of the tetanus toxoid vaccine are redness and pain at the site of
injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most
serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000
people. The market for tetanus toxoid vaccine is bipolar with contractual market having a
sizable number of share as compared to the private market. The other market constraints
include falling profitability of vaccine manufacturing, huge reduction of tetanus in the
developed world which effectively eliminates the need for further vaccination due to herd
immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid
vaccine etc.
The low profitability in vaccine manufacturing has reduced incentives for developing
vaccines for diseases of the developing world such as tuberculosis and malaria.
Considering all these factors, the market for Tetanus toxoid vaccine is expected to reach $
5.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 5.3 %
during 2017-2023.
Key players of Global Tetanus toxoid vaccine market:
Top Market Vendors are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur,
Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant
Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and
others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4024 .